Excessive doses of anabolic steroids can induce harmful changes in cholesterol, acne, hypertension, liver damage, and damage to the heart. Hormonal imbalances caused by the use of anabolic steriods may result in gynecomastia and testicular atrophy.
Anabolic steroids are known to increase harmful LDL, while decreasing beneficial HDL cholesterol. Their ability to stimulate sebaceous glands may increase acne. Additionally, the elevation in blood pressure caused by anabolic steroids, is particularly pronounced and harmful in those with pre-existing hypertension.
4-Hydroxytestosterone is testosterone substituted with a hydroxy group on the fourth carbon atom. It is an anabolic steroid with no therapeutic indications, which is prohibited from use in sports by the World Anti-Doping Agency.
Formestane (Lentaron) acts as a prohormone of 4-Hydroxytestosterone, as 4-Hydroxytestosterone is one of the many byproducts of formestane metabolism. It is specifically the 17-hydroxylated analog to formestane. A14385 Like formestane, 4-hydroxytesterone has been patented for use in decreasing estrogen production in the body, but no such indication currently exists. 4-Hydroxytestosterone was first patented in 1955 by G.D Searle & Company.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Prasterone | The serum concentration of 4-Hydroxytestosterone can be increased when it is combined with Prasterone. |
| Dextrose, unspecified form | The serum concentration of Dextrose, unspecified form can be decreased when it is combined with 4-Hydroxytestosterone. |
| Propranolol | 4-Hydroxytestosterone may increase the excretion rate of Propranolol which could result in a lower serum level and potentially a reduction in efficacy. |
| Flunisolide | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Flunisolide. |
| Beclomethasone dipropionate | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Beclomethasone dipropionate. |
| Betamethasone | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Betamethasone. |
| Fluticasone propionate | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Fluticasone propionate. |
| Fluocinolone acetonide | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Fluocinolone acetonide. |
| Triamcinolone | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Triamcinolone. |
| Prednisone | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Prednisone. |
| Fludrocortisone | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Fludrocortisone. |
| Hydrocortisone | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Hydrocortisone. |
| Prednisolone | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Prednisolone. |
| Methylprednisolone | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Methylprednisolone. |
| Trilostane | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Trilostane. |
| Budesonide | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Budesonide. |
| Dexamethasone | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Dexamethasone. |
| Corticotropin | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Corticotropin. |
| Cortisone acetate | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Cortisone acetate. |
| Paramethasone | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Paramethasone. |
| Ciclesonide | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Ciclesonide. |
| Aldosterone | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Aldosterone. |
| Fluticasone furoate | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Fluticasone furoate. |
| Fluprednidene | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Fluprednidene. |
| Tixocortol | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Tixocortol. |
| Fluprednisolone | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Fluprednisolone. |
| Meprednisone | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Meprednisone. |
| Dexamethasone isonicotinate | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Dexamethasone isonicotinate. |
| Melengestrol | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Melengestrol. |
| Deflazacort | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Deflazacort. |
| Cortivazol | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Cortivazol. |
| Prednylidene | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Prednylidene. |
| Fluocortin | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Fluocortin. |
| Fluperolone | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Fluperolone. |
| Cloprednol | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Cloprednol. |
| Fluclorolone | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Fluclorolone. |
| Fluticasone | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Fluticasone. |
| Mometasone furoate | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Mometasone furoate. |
| Hydrocortisone acetate | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Hydrocortisone acetate. |
| Hydrocortisone cypionate | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Hydrocortisone cypionate. |
| Hydrocortisone succinate | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Hydrocortisone succinate. |
| Prednisolone phosphate | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Prednisolone phosphate. |
| Prednisolone hemisuccinate | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Prednisolone hemisuccinate. |
| Methylprednisolone hemisuccinate | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Methylprednisolone hemisuccinate. |
| Prednisone acetate | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Prednisone acetate. |
| Clocortolone acetate | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Clocortolone acetate. |
| Melengestrol acetate | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Melengestrol acetate. |
| Betamethasone phosphate | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Betamethasone phosphate. |
| Cortisone | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Cortisone. |
| Clobetasol propionate | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Clobetasol propionate. |
| Fluocinonide | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Fluocinonide. |
| Hydrocortisone butyrate | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Hydrocortisone butyrate. |
| Desoximetasone | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Desoximetasone. |
| Mometasone | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Mometasone. |
| Fluocortolone | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Fluocortolone. |
| Prednisolone acetate | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Prednisolone acetate. |
| Fluorometholone | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Fluorometholone. |
| Difluocortolone | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Difluocortolone. |
| Flumethasone | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Flumethasone. |
| Methylprednisolone aceponate | The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Methylprednisolone aceponate. |
| Lepirudin | 4-Hydroxytestosterone may increase the anticoagulant activities of Lepirudin. |
| Bivalirudin | 4-Hydroxytestosterone may increase the anticoagulant activities of Bivalirudin. |
| Alteplase | 4-Hydroxytestosterone may increase the anticoagulant activities of Alteplase. |
| Urokinase | 4-Hydroxytestosterone may increase the anticoagulant activities of Urokinase. |
| Reteplase | 4-Hydroxytestosterone may increase the anticoagulant activities of Reteplase. |
| Anistreplase | 4-Hydroxytestosterone may increase the anticoagulant activities of Anistreplase. |
| Tenecteplase | 4-Hydroxytestosterone may increase the anticoagulant activities of Tenecteplase. |
| Abciximab | 4-Hydroxytestosterone may increase the anticoagulant activities of Abciximab. |
| Drotrecogin alfa | 4-Hydroxytestosterone may increase the anticoagulant activities of Drotrecogin alfa. |
| Streptokinase | 4-Hydroxytestosterone may increase the anticoagulant activities of Streptokinase. |
| Dicoumarol | 4-Hydroxytestosterone may increase the anticoagulant activities of Dicoumarol. |
| Argatroban | 4-Hydroxytestosterone may increase the anticoagulant activities of Argatroban. |
| Ardeparin | 4-Hydroxytestosterone may increase the anticoagulant activities of Ardeparin. |
| Phenindione | 4-Hydroxytestosterone may increase the anticoagulant activities of Phenindione. |
| Fondaparinux | 4-Hydroxytestosterone may increase the anticoagulant activities of Fondaparinux. |
| Warfarin | 4-Hydroxytestosterone may increase the anticoagulant activities of Warfarin. |
| Pentosan polysulfate | 4-Hydroxytestosterone may increase the anticoagulant activities of Pentosan polysulfate. |
| Phenprocoumon | 4-Hydroxytestosterone may increase the anticoagulant activities of Phenprocoumon. |
| Dipyridamole | 4-Hydroxytestosterone may increase the anticoagulant activities of Dipyridamole. |
| Heparin | 4-Hydroxytestosterone may increase the anticoagulant activities of Heparin. |
| Enoxaparin | 4-Hydroxytestosterone may increase the anticoagulant activities of Enoxaparin. |
| Epoprostenol | 4-Hydroxytestosterone may increase the anticoagulant activities of Epoprostenol. |
| Acenocoumarol | 4-Hydroxytestosterone may increase the anticoagulant activities of Acenocoumarol. |
| 4-hydroxycoumarin | 4-Hydroxytestosterone may increase the anticoagulant activities of 4-hydroxycoumarin. |
| Coumarin | 4-Hydroxytestosterone may increase the anticoagulant activities of Coumarin. |
| Ximelagatran | 4-Hydroxytestosterone may increase the anticoagulant activities of Ximelagatran. |
| Desmoteplase | 4-Hydroxytestosterone may increase the anticoagulant activities of Desmoteplase. |
| Defibrotide | 4-Hydroxytestosterone may increase the anticoagulant activities of Defibrotide. |
| Ancrod | 4-Hydroxytestosterone may increase the anticoagulant activities of Ancrod. |
| Beraprost | 4-Hydroxytestosterone may increase the anticoagulant activities of Beraprost. |
| Prasugrel | 4-Hydroxytestosterone may increase the anticoagulant activities of Prasugrel. |
| Rivaroxaban | 4-Hydroxytestosterone may increase the anticoagulant activities of Rivaroxaban. |
| Sulodexide | 4-Hydroxytestosterone may increase the anticoagulant activities of Sulodexide. |
| Semuloparin | 4-Hydroxytestosterone may increase the anticoagulant activities of Semuloparin. |
| Idraparinux | 4-Hydroxytestosterone may increase the anticoagulant activities of Idraparinux. |
| Cangrelor | 4-Hydroxytestosterone may increase the anticoagulant activities of Cangrelor. |
| Astaxanthin | 4-Hydroxytestosterone may increase the anticoagulant activities of Astaxanthin. |
| Apixaban | 4-Hydroxytestosterone may increase the anticoagulant activities of Apixaban. |
| Otamixaban | 4-Hydroxytestosterone may increase the anticoagulant activities of Otamixaban. |
| Amediplase | 4-Hydroxytestosterone may increase the anticoagulant activities of Amediplase. |